Hims & Hers Health Stock Is Plunging Tuesday: What's Going On?

Hims & Hers Health Inc HIMS shares are tumbling Tuesday on the heels of the company’s fourth-quarter financial results. Here’s what you need to know.

What Happened: Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to Benzinga Pro. The company reported fourth-quarter earnings of 11 cents per share, in line with analyst estimates.

Total revenue was up 69% on a year-over-year basis. Subscribers grew to 2.2 million in the quarter, up 45% year-over-year. Gross margin was 77% in the fourth quarter, which came up short of analyst estimates of 78.4%, according to CNBC.

Hims & Hers Health shares have been on a tear since the company said it would begin selling compounded versions of GLP-1 injections last year. The stock fell more than 20% on Friday after the U.S. Food and Drug Administration removed semaglutide injections from the shortage list. Hims & Hers said this week that its GLP-1 offering brought in over $225 million in revenue in 2024.

“2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system,” said Andrew Dudum, co-founder and CEO of Hims & Hers Health.

“In the coming years, we expect to further transform how individuals can improve their health with more comprehensive treatments, technologies that normalize unlimited follow up support, and tools that can eventually be exported beyond Hims and Hers, enabling even more Americans to access this care.”

See Also: DocuSign Boasts 13% Revenue Growth In Q4, Raises Full-Year Guidance Due To AI Momentum

Hims & Hers Health guided for first-quarter revenue of $520 million to $540 million. The company expects full-year 2025 revenue to be in the range of $2.3 billion to $2.4 billion versus estimates of $2.087 billion, according to Benzinga Pro.

Following the company’s quarterly results, Citigroup analyst Daniel Grosslight maintained Hims & Hers with a Sell and raised the price target from $25 to $27. Needham analyst Ryan MacDonald maintained a Buy rating and raised the price target from $31 to $61.

HIMS Price Action: Hims & Hers Health shares were down 19.6% at $41.15 at the time of publication Tuesday, according to Benzinga Pro.

Photo: Shutterstock.